AI team at In­sil­i­co gets some ma­jor league back­ing from Chi­na as Alex Zha­voronkov builds glob­al net­work

Some of Asia’s top biotech in­vestors are back­ing Alex Zha­voronkov’s AI shop at In­sil­i­co Med­i­cine.

It’s a long way from a megaround, falling in­to an un­spec­i­fied slot in the $5 mil­lion to $10 mil­lion range, but Zha­voronkov has al­lied him­self with some of the most in­ter­est­ing peo­ple in drug de­vel­op­ment. And he’s us­ing this new mon­ey to ex­pand his glob­al net­work of AI ex­perts as he im­me­di­ate­ly be­gins to go af­ter a new raise to back a big­ger game plan.

Ge Li

This new round is led by WuXi AppTec, the high-fly­ing dis­cov­ery and de­vel­op­ment out­fit based in Shang­hai and helmed by Ge Li, who of­fered an in­flu­en­tial shout out by not­ing that the two com­pa­nies share a “mu­tu­al vi­sion that ar­ti­fi­cial in­tel­li­gence and ma­chine learn­ing will op­ti­mize the drug dis­cov­ery process by in­creas­ing the prob­a­bil­i­ty of suc­cess at the pre-clin­i­cal lev­el.”

Sin­ga­pore’s Temasek al­so got in­volved, along with Pe­ter Dia­man­dis’ — of X Prize fame — BOLD Cap­i­tal. Longevi­ty biotech Ju­ve­nes­cence, backed by UK bil­lion­aire Jim Mel­lon and al­lied with Zha­voronkov’s AI op­er­a­tion, al­so came back to chip in­to the round.

“We have col­lab­o­rat­ed with WuXi for over a year now,” Zha­voronkov tells me, “we know them.”

Be­fore Ge Li and his col­leagues de­cid­ed to back the AI shop, he ex­plained in a pre­view to the an­nounce­ment, they start­ed out a year ago val­i­dat­ing their work us­ing known path­ways. Zha­voronkov has been us­ing ma­chine learn­ing to build mol­e­cules, and he start­ed out by prov­ing that he could do it on projects with well un­der­stood bi­ol­o­gy. Now that they’ve passed that test, WuXi and In­sil­i­co are go­ing in­to vir­gin ter­ri­to­ry, build­ing new mol­e­cules aimed at or­phan tar­gets “from scratch” us­ing a neur­al net­work as they build a new dis­cov­ery plat­form with WuXi’s top chemists.

Zha­voronkov poured every­thing he has in­to the com­pa­ny to get it start­ed, and these grow­ing in­ter­na­tion­al con­nec­tions are cen­tral to build­ing the com­pa­ny. In­sil­i­co now has 52 staffers spread from new of­fices in Rockville, MD in­to Eu­rope, Rus­sia and Asia, where a team of 6 work in Tai­wan. His next step, he says, is aimed right at the ex­plod­ing Chi­nese mar­ket.

In AI, he says, “if you’re not in Chi­na now, you’re not go­ing to ex­ist.”

In the mean­time, he’s fo­cused on build­ing his busi­ness de­vel­op­ment team, look­ing to re­cruit some new play­ers.

AI shops have been boom­ing is a va­ri­ety of big op­er­a­tions con­sid­er the ways the tech­nol­o­gy can be used to stream­line drug de­vel­op­ment and im­prove odds of suc­cess — a propo­si­tion that still has a con­sid­er­able ways to go be­fore we start see­ing how it can af­fect the out­put of new drugs that go in­to hu­man test­ing. For big com­pa­nies deeply en­gaged in dis­cov­ery, though, it re­mains a com­pelling ap­proach to pipeline build­ing.

Just a few weeks ago Zha­voronkov al­lied with George Church on a col­lab­o­ra­tion mix­ing Neb­u­la Ge­nomics’ blockchain work with his deep learn­ing ex­perts to build a new plat­form for health­care da­ta. And he con­tin­ues to build re­la­tions with some of the most close­ly watched de­vel­op­ers in the in­dus­try, in­clud­ing Glax­o­SmithK­line.


Im­age: Alex Zha­voronkov. HEALTH TECH­NOLO­GIES TV via YOUTUBE

Noubar Afeyan, Flagship founder and CEO (Victor Boyko/Getty Images)

UP­DAT­ED: Flag­ship launch­es Sen­da Bio­sciences with an $88M back­ing, look­ing to pi­o­neer the field of 'In­ter­sys­tems Bi­ol­o­gy'

Flagship Pioneering has a fresh company out this week, one that aims to lay the groundwork for a whole new discipline.

Senda Biosciences launched Wednesday with $88 million in Flagship cash. The goal? Gain insights into the molecular connections between people and coevolved nonhuman species like plants and bacteria, paving the way for “Intersystems Biology.”

Guillaume Pfefer has been tapped to run the show, a 25-year biotech veteran who comes from GSK after leading the development of the company’s shingles vaccine.

Daphne Koller, Getty

Bris­tol My­er­s' Richard Har­g­reaves pays $70M to launch a neu­rode­gen­er­a­tion al­liance with a star play­er in the ma­chine learn­ing world

Bristol Myers Squibb is turning to one of the star upstarts in the machine learning world to go back to the drawing board and come up with the disease models needed to find drugs that can work against two of the toughest targets in the neuro world.

Daphne Koller’s well-funded insitro is getting $70 million in cash and near-term milestones to use their machine learning platform to create induced pluripotent stem cell-derived disease models for ALS and frontotemporal dementia.

Q32 Bio grabs $60M to kick off hu­man stud­ies for next-gen com­ple­ment drugs — with some Covid-19 tweaks along the way

For a company that launched in the early months of the pandemic, Q32 Bio had its fair share of run-ins with the new normals under Covid-19.

The original plan, for instance, was to conduct first-in-human studies of the IL-7 receptor antibody it licensed from Bristol Myers Squibb in the Netherlands. But they realized shortly after that while the country was beginning to open up clinical trials, there were additional restrictions on drugs that tampered with immunological mechanisms.

Konstantin Poukalov

Per­cep­tive re­cruits A-list in­vestors to back its in-house Chi­na start­up with a mam­moth $310M raise

It took two years for Perceptive Advisors to conceive and boot up LianBio, its big bet on a new kind of in-licensing model for China, seeding it with enough cash to set up two anchoring deals with MyoKardia and BridgeBio. The result was a startup that was all ready to go, reaping $310 million just a little over two months after official launch.

Homegrown Chinese biotechs — many of them boasting of US ties and execs with overseas credentials — have been raking in mega-venture rounds in 2020, both from influential local backers and overseas VC firms that have been loading up new cash. As with IPOs, the deal flow might be slower but the amounts are often more staggering. LianBio’s latest round, unusually, is branded both a Series A and crossover.

Eli Lilly CEO David Ricks at the Rose Garden, May 26, 2020 (Evan Vucci/AP Images)

Eli Lil­ly lines up a block­buster deal for Covid-19 an­ti­body, right af­ter it failed a NI­AID tri­al

Two days after Eli Lilly conceded that its antibody bamlanivimab was a flop in hospitalized Covid-19 patients, the US government is preparing to make it a blockbuster.

The pharma giant reported early Wednesday that it struck a deal to supply the feds with 300,000 vials of the drug at a cost of $375 million — once it gets an EUA stamp from the FDA. And once that 2-month supply deal is done, the government has an option on another 650,000 doses on the same terms — which could potentially add another $812 million.

Ar­cus and As­traZeneca part­ner on a high stakes an­ti-TIG­IT/PD-L1 PhI­II can­cer study, look­ing to im­prove on a stan­dard of care

For AstraZeneca, the PACIFIC trial in Stage III non-small cell lung cancer remains one of the big triumphs for AstraZeneca’s oncology R&D group. It not only made their PD-L1 Imfinzi a franchise player with a solid advance in a large niche of the lung cancer market, the study — which continues to offer data on the long-range efficacy of their drug — also helped salve the vicious sting of the failure of the CTLA-4 combo in the MYSTIC study.

No­var­tis buys a new gene ther­a­py for vi­sion loss, and this is one pre­clin­i­cal ven­ture that did­n't come cheap

Cyrus Mozayeni got excited when he began to explore the academic work of Ehud Isacoff and John G. Flannery at UC Berkeley.

Together, they were engaged in finding a gene therapy approach to pan-genotypic vision restoration in patients with photoreceptor-based blindness, potentially restoring the vision of a broad group of patients. And they did it by using a vector to deliver the genetic sequence for light sensing proteins.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,800+ biopharma pros reading Endpoints daily — and it's free.

CMO Merdad Parsey (Gilead)

Gilead hits the brakes on a tri­fec­ta of mid- and late-stage stud­ies for their trou­bled fil­go­tinib pro­gram. It's up to the FDA now

Gilead $GILD execs haven’t decided exactly what to do with filgotinib in the wake of the slapdown at the FDA on their rheumatoid arthritis application, but they’re taking a time out for a slate of studies until they can gain some clarity from the agency. And without encouraging guidance, this drug could clearly be axed from the pipeline.

In their Q3 report out Wednesday afternoon, the company says researchers have “paused” a Phase III study for psoriatic arthritis along with a pair of Phase II trials for ankylosing spondylitis and uveitis. Late-stage studies for ulcerative colitis and Crohn’s are continuing, but you can see for yourself how big a hole this leaves in the inflammatory disease pipeline, with obvious implications if the company abandons filgo altogether.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,800+ biopharma pros reading Endpoints daily — and it's free.

Managing partner Stefan Fischer (TVM)

Eli Lil­ly part­ner TVM Cap­i­tal rais­es $478M for their new life sci­ences fund, a 'sub­stan­tial' over­sub­scrip­tion

A German-Canadian VC fund and high-profile Eli Lilly partner has nearly half a billion dollars in new cash to play with.

TVM Capital Life Science, based out of Munich and Montreal, announced the closing of its second and latest fund Tuesday with $478 million in hand. That total represents a “substantial” oversubscription, managing partner Stefan Fischer said, and a good 36.5% more than the $350 million initially expected.